vinflunine + methotrexate

Vinflunine + methotrexate is an intravenous combination chemotherapy regimen studied primarily for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in patients who have previously received platinum-based therapy. Vinflunine is a novel fluorinated vinca alkaloid that acts as a microtubule inhibitor, disrupting cell division, while methotrexate is an antimetabolite and antifolate agent that inhibits dihydrofolate reductase, blocking DNA synthesis. The combination aims to improve efficacy compared to methotrexate alone, with phase I and III clinical trials indicating manageable toxicity and preliminary antitumor activity. Pharmacokinetic studies indicate no significant interaction between the drugs when given together[1][4][6].